US › Healthcare

Keros Therapeutics Inc (KROS)

US · Healthcare · Biotechnology

$10.25+1.38%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$367,000
Revenue YoY
-99.8%
Net profit
$-23.7M
Profit YoY
-116.0%
EPS
$-1.21
EPS estimate
$-0.73
Net margin
-6,459.9%

EPS came in at -1.21 against a street estimate of -0.73 — a miss of 66.2%.

Key statistics

Market cap
$199.3M
Forward P/E
15.6
P/B
0.70
Book value
$14.47
EPS (TTM)
$-2.53
52-week high
$22.55
52-week low
$9.69
50-day MA
$10.71
200-day MA
$14.25
Beta
0.97

Analyst view

Analysts rate Keros Therapeutics Inc a buy (7 buy, 6 hold, 0 sell out of 13) with an average price target of $21.83.

Shareholding

Insiders
3.71%
Institutions
94.79%

Largest institutional holders

FundStake
BlackRock Inc12.19%
Nantahala Capital Management, LLC6.87%
Vanguard Capital Management, LLC4.20%
Orbimed Advisors, LLC3.84%
Qube Research & Technologies3.66%
Jacobs Levy Equity Management, Inc.3.57%
Federated Hermes Inc3.48%
Vanguard Portfolio Management, LLC3.45%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Keros Therapeutics Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.